Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986172 · 1 trial · 1 indication
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave
| Arm | Type | Description |
|---|---|---|
| Part A: SAD | EXPERIMENTAL | SAD = Single Ascending Dose |
| Part B: MAD | EXPERIMENTAL | MAD = Multiple Ascending Dose |
| Part C: JMAD | EXPERIMENTAL | JMAD= Japanese Multiple Ascending Dose |
| Part D: FE/BA | EXPERIMENTAL | FE/BA = Food Effect/Relative Bioavailability |
| Name | Type | Description |
|---|---|---|
| BMS-986172 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Healthy participants as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, ECG, and clinical laboratory results as determined by the investigator or designee. * Participants in Part C must be first-generation Ja...
BMS-986172 is an investigational small molecule being developed by Bristol-Myers Squibb Company. It has been studied in a Phase 1 clinical trial in healthy and obese participants to assess its safety, tolerability, and drug levels. The specific therapeutic indication for BMS-986172 has not been disclosed.
BMS-986172 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company sponsored the Phase 1 trial of BMS-986172 in healthy and obese participants.
BMS-986172 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
BMS-986172 has been evaluated in a single Phase 1 trial, NCT04926051, titled "A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption." The trial enrolled 40 participants in the United States and is completed.
The molecular target of BMS-986172 has not been disclosed. Bristol-Myers Squibb has not publicly identified the specific receptor or enzyme that BMS-986172 modulates.